A PYMNTS Company

Brazil’s Watchdog Clears Hurdle For Hypera-Takeda Deal 

By  |  January 20, 2021

Brazil’s antitrust regulator CADE announced on Wednesday, January 20, it had cleared the way for Hypera Pharma to buy a portfolio of productions from Japan’s Takeda Pharmaceutical.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    According to a source familiar with the matter, there was only one restriction, and it involved the medicine Xantinon, which Hypera has already sold locally to União Química Farmacêutica Nacional. Hypera had told investors it was expecting this approval in early 2021.

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.